Last updated: February 24, 2026
What Does Patent CA2897900 Cover?
Patent CA2897900, titled "Methods of treating or preventing cancer," is granted to a pharmaceutical company for a combination therapy involving a MEK inhibitor and a CDK4/6 inhibitor. The patent was filed on September 10, 2013, and issued on October 25, 2016.
Core Invention
- Combination of a MEK inhibitor with a CDK4/6 inhibitor for treating cancers, particularly melanoma and other solid tumors.
- Specific use cases include inhibiting tumor cell proliferation by concurrently targeting the MAPK pathway and cell cycle regulation.
Patent Claims
The patent contains 15 claims, primarily focused on:
- Method of treatment claims (1-7): Use of the combination in treating cancers with specific dosages.
- Composition claims (8-11): Pharmaceutical compositions comprising the two inhibitors.
- Kits and dosage regimen claims (12-15): Use of combinations for specific treatment protocols.
Scope of Claims
- Treatment methods involve administering a therapeutically effective amount of a MEK inhibitor and a CDK4/6 inhibitor.
- Target indications mainly include melanoma, breast cancer, and other solid tumors bearing mutations in the MAPK pathway.
- Inhibitors specified include trametinib (MEK inhibitor) and palbociclib (CDK4/6 inhibitor), among others.
Patent Landscape
Patent Family and Geographic Coverage
- The patent family extends into the US, Europe, Australia, Japan, and China.
- The Canadian patent aligns with corresponding patents in these jurisdictions, with similar claims covering methods and compositions.
Competitive Landscape
- The patent intersects with multiple prior arts focused on combination therapies in oncology.
- Notably, the claims overlap with patents owned by pharmaceutical companies such as Novartis and Pfizer, targeting similar pathways.
Patent Validity and Challenges
- The patent has not faced significant post-grant opposition or litigation in Canada.
- Prior art references include US patents 8,541,268 and 8,586,469, which describe similar combinations.
- The patent’s novelty hinges on specific dosing regimens and combination specifics that distinguish it from prior art.
Expiry Date
- The patent is set to expire on September 10, 2033, assuming maintenance fees are paid and no extensions are granted.
Market and R&D Implications
- The patent covers key combination therapies for melanoma and other tumors, potentially blocking generic development until expiry.
- The patent's scope includes formulations, dosages, and specific treatment methods, making it a broad barrier in Canada.
- It aligns with ongoing clinical trials for combination therapies involving MEK and CDK4/6 inhibitors, which target resistance mechanisms in cancer treatment.
Summary of Key Legal and Strategic Points
- The claims focus on methods, compositions, and treatment regimens involving MEK and CDK4/6 inhibitors.
- The patent provides broad coverage over treatment indications in solid tumors, notably melanoma.
- Similar patents exist globally; the patent's strength in Canada is reinforced by the lack of known litigations or oppositions.
- The patent’s expiration in 2033 provides a window for commercial exclusivity and investment planning.
Key Takeaways
- CA2897900 grants broad rights to combination therapy for cancer, especially melanoma.
- The patent landscape indicates a crowded arena with other patents targeting the same mechanisms.
- Vigilance required for potential invalidation based on prior art, especially in the US and Europe.
- The patent supports R&D strategies around combination therapy in oncology markets.
FAQs
What are the main patent claims?
Claims predominantly cover methods, pharmaceutical compositions, and treatment protocols involving MEK and CDK4/6 inhibitors for cancer treatment.
Is the patent enforceable in Canada?
Yes, the patent is granted and enforceable until 2033, subject to maintenance.
How does the patent compare to existing ones?
It expands on prior art by defining specific combination treatment methods and formulations, but faces competition from similar patents.
What cancers are targeted?
Primarily melanoma, breast cancer, and other solid tumors with relevant mutations.
What are the risks of patent invalidation?
Prior art references and incomplete novelty or inventive step arguments could challenge validity, especially if similar combinations are patented elsewhere.
References
- Canadian Intellectual Property Office. (2016). Patent CA2897900.
- U.S. Patent No. 8,541,268.
- U.S. Patent No. 8,586,469.
- ClinicalTrials.gov. (2023). Trials involving MEK and CDK4/6 inhibitors.
- European Patent Office. Patent family documents.
